Skip header and navigation

Refine By

42 records – page 1 of 5.

Amino acids and their derivatives in blood plasma of patients with breast cancer treated with Ukrain. Part V.

https://arctichealth.org/en/permalink/ahliterature22892
Source
Drugs Exp Clin Res. 1996;22(3-5):155-7
Publication Type
Article
Date
1996
Author
L I Nefyodov
K N Uglyanica
V Y Smirnov
Y M Doroshenko
K A Fomin
J W Nowicky
W J Brzosko
Author Affiliation
Institute of Biochemistry, Belarussian Academy of Sciences, Grodno, Belarus.
Source
Drugs Exp Clin Res. 1996;22(3-5):155-7
Date
1996
Language
English
Publication Type
Article
Keywords
Alkaloids - therapeutic use
Amino Acids - blood
Antineoplastic Agents - therapeutic use
Breast Neoplasms - blood - drug therapy - surgery
Combined Modality Therapy
Female
Humans
Abstract
The present study was undertaken to evaluate the influence of Ukrain on the free amino acids pool in blood plasma in ten patients with breast cancer, treated in the preoperative phase with the drug. The control group consisted of five patients of similar age and advancement of the disease, who did not receive Ukrain before mastectomy. The data obtained from these studies indicate that Ukrain positively influences the metabolism of amino acids and their derivatives. The most characteristic changes were increase of proline, taurine and glutamic acid.
PubMed ID
8899320 View in PubMed
Less detail

Amino acids and their derivatives in tumour tissue from patients with breast cancer treated with Ukrain. Part VI.

https://arctichealth.org/en/permalink/ahliterature22891
Source
Drugs Exp Clin Res. 1996;22(3-5):159-61
Publication Type
Article
Date
1996
Author
L I Nefyodov
K N Uglyanica
V Y Smirnov
Y M Doroshenko
K A Fomin
J W Nowicky
W J Brzosko
Author Affiliation
Institute of Biochemistry, Belarussian Academy of Sciences, Grodno, Belarus.
Source
Drugs Exp Clin Res. 1996;22(3-5):159-61
Date
1996
Language
English
Publication Type
Article
Keywords
Alkaloids - therapeutic use
Amino Acids - metabolism
Antineoplastic Agents - therapeutic use
Breast Neoplasms - drug therapy - metabolism - surgery
Combined Modality Therapy
Female
Humans
Abstract
The present study was undertaken to evaluate the influence of Ukrain on the amino acids pool and their derivatives in tumour tissue of ten patients with breast cancer, treated in the preoperative phase with Ukrain. The control group consisted of five patients of similar age and advancement of the disease, who did not receive Ukrain. The data obtained indicate that Ukrain influences cancerous tissue, as demonstrated at the level of amino acids. The most characteristic changes observed in cancerous tissue after treatment with Ukrain were increases in the levels of proline, taurine and glutamic acid.
PubMed ID
8899321 View in PubMed
Less detail

[Changes in amino acid patterns of blood plasma in tumor patients treated with anticancer drug NSC-631570: possible approaches to cancer diagnostics]

https://arctichealth.org/en/permalink/ahliterature92449
Source
Biomed Khim. 2008 May-Jun;54(3):289-300
Publication Type
Article
Author
Glazev A A
Nefedov L I
Source
Biomed Khim. 2008 May-Jun;54(3):289-300
Language
Russian
Publication Type
Article
Keywords
Amino Acids - blood
Antineoplastic Agents - therapeutic use
Berberine Alkaloids - therapeutic use
Discriminant Analysis
Humans
Neoplasms - diagnosis - drug therapy - metabolism
Phenanthridines - therapeutic use
Plasma
Stochastic Processes
Abstract
In our early experimental (with W-256, SM-1 and PC-1 tumors) and clinical (breast, bladder and prostate cancers) studies the use of the anticancer drug NSC-631570 was proven to be safe and highly effective, inhibiting protein synthesis in cancer cells, selectively accumulating in cancer tissue after a single intravenous administration and controlling cancer-induced metabolic imbalance. This drug inhibits metabolic processes in the tumor and causes metabolic disorders in cancer cells. Moreover, NSC-631570 induced the changes in certain amino acids concentrations in biological fluids and tumor tissue in animal models and cancer patients. These changes cannot be explained by metabolic amino acid disorders in cancer known so far. In this study the effects of NSC-631570 on blood plasma amino acids has been investigated. Blood was sampled from 10 healthy donors and 29 patients with different types of cancer (stomach, rectal, lung, breast, bladder, prostate, and leukemia). Comparison of NSC-531570 effects in plasma of healthy donors and cancer patients has shown, that this compoumd: 1) affects amino acids with positively charged (His, Arg) or not charged (Tyr, Thr, Gln) R-groups; 2) decreases concentration of His and increase the concentrations of beta-Ala and Tau. These changes depend on the concentration of NSC-631570 and the type of cancer. On the basis of the literature data and the results of our studies we suggest that Ukrain's biological actions in cancer are realized at least partly through selective interaction with amino acids, their derivatives, and plasma proteins. These data provide the background for the using Ukrain in the cancer detection and investigating the mechanisms of carcinogenesis.
PubMed ID
18712085 View in PubMed
Less detail

Comparative evaluation of blood plasma and tumor tissue amino acid pool in radiation or neoadjuvant preoperative therapies of breast cancer with the antitumor drug Ukrain.

https://arctichealth.org/en/permalink/ahliterature19818
Source
Drugs Exp Clin Res. 2000;26(5-6):231-7
Publication Type
Article
Date
2000
Author
L I Nefyodov
K N Uglyanitsa
V Y Smirnov
A V Karavay
W. Brzosko
Author Affiliation
Laboratory of Analytical Biochemistry, Institute of Biochemistry, National Academy of Sciences of Belarus, 50 BLK, Grodno 230017, Belarus.
Source
Drugs Exp Clin Res. 2000;26(5-6):231-7
Date
2000
Language
English
Publication Type
Article
Keywords
Adult
Alkaloids - therapeutic use
Amino Acids - blood - metabolism
Antineoplastic Agents, Phytogenic - therapeutic use
Breast Neoplasms - metabolism - therapy
Chemotherapy, Adjuvant
Combined Modality Therapy
Comparative Study
Female
Humans
Mastectomy
Middle Aged
Postoperative Period
Abstract
This study comparatively evaluated free amino acid pool formation in patients with T1-3N0-2M0 breast cancer treated with the drug Ukrain (25 patients, i.v. 100 mg/course) in combination with preoperative radiation or neoadjuvant therapies (25 subjects, total dose 20 Gy). All the patients underwent radical mastectomy. Preoperative radiation did not essentially change the range of the blood plasma parameters studied. However, we observed decreased concentrations of blood plasma ornithine and citrulline and a reduced content of aminobutyric acid, as compared with levels on admission, which may indicate an acceleration of detoxication processes in the liver. In comparison with healthy mammary gland tissue, the tumor tissue of the patients subjected to radiation therapy showed 1.5- to twofold increased concentrations of cysteate, taurine, aspartate, glutamate, proline, glycine, alanine, valine, tyrosine and histidine, which substantiates the idea of tumor tissue being a trap for numerous energy and plastic substrates and indicates active transport of the above compounds into the tumor. The application of Ukrain had virtually no influence on concentrations of the majority of blood plasma amino acids and derivatives: the total concentration of the compounds studied as well as the essential and nonessential amino acid pools remained unchanged. As compared with healthy breast tissue, the considerably increased levels of thiol-containing amino acids, such as methionine, cystine, cysteate and taurine, in the tumor tissue of patients receiving neoadjuvant therapy with Ukrain, indicates high activity of trans-sulfuration processes in this tissue. Simultaneously, in contrast to radiation therapy, Ukrain induced a marked dose-dependent increase in the concentration of proline in breast tumor tissue. The above changes were consistent with the results of the morphological study which confirmed the emergence of numerous foci of necrosis in the tumor and indicated activation of Ukrain-induced proteolytic and degradation processes in the tumor. The results obtained have led us to conclude that a mechanism of Ukrain's cancerostatic effect is to control the transport and reactions of intermediate amino acid metabolism as well as to activate proline biosynthesis in the tumor, causing enhanced development of connective tissue. It is suggested that an important practical conclusion from the present study is the lack of damaging effect of preoperative radiation therapy in the above regimen and the favorable (normalizing) action of Ukrain, at a course dose of 100 mg, on the amino acid pool formation in the organism of patients with breast cancer.
PubMed ID
11345030 View in PubMed
Less detail

Comparative evaluation of the complex treatment of rectal cancer patients (chemotherapy and X-ray therapy, Ukrain monotherapy).

https://arctichealth.org/en/permalink/ahliterature21121
Source
Drugs Exp Clin Res. 1998;24(5-6):221-6
Publication Type
Article
Date
1998
Author
G V Bondar
A V Borota
Y I Yakovets
S E Zolotukhin
Author Affiliation
Donetsk Regional Anti-Cancer Center, Ukraine.
Source
Drugs Exp Clin Res. 1998;24(5-6):221-6
Date
1998
Language
English
Publication Type
Article
Keywords
Adult
Aged
Alkaloids - therapeutic use
Antineoplastic Agents - therapeutic use
Combined Modality Therapy
Comparative Study
Female
Fluorouracil - therapeutic use
Humans
Male
Middle Aged
Rectal Neoplasms - therapy
X-Ray Therapy
Abstract
A total of 48 patients suffering from rectum cancer were included in this randomized study conducted at the Proctology Department of the Donetsk Regional Anti-Cancer Center. Patients in group I (24 patients) received an intensive course of high fractional X-ray therapy (cumulative dose up to 25 Gy) with direct protracted endolymphatic chemotherapy with 5-fluorouracil (5-FU) instilled in 600 mg/m2 each day before operation, up to a cumulative dose of 5 g. The 24 patients in group II were treated with Ukrain as monotherapy, 10 mg each second day before operation (up to a cumulative dose of 60 mg) and a total of 40 mg after surgical intervention. Repeated Ukrain courses (100 mg/per course) were also given 6 months after surgical operation. In each ease preoperative treatment was followed by routine surgical operation. Prolongation morbi were found to have developed 14 months later in six patients in group I (25.0%), whereas in group II they were found only in two cases (8.3%). Comparative investigation of objective and subjective signs, analysis of results of instrument and X-ray data, as well as dynamic study of the histological structure of rectal tumors, indicate that Ukrain exerts a more potent malignotoxic and immunomodulating action than other types of anticancer treatment.
PubMed ID
10190078 View in PubMed
Less detail

Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer.

https://arctichealth.org/en/permalink/ahliterature22899
Source
Drugs Exp Clin Res. 1996;22(3-5):115-22
Publication Type
Article
Date
1996
Author
Y M Susak
V S Zemskov
O Y Yaremchuk
O B Kravchenco
I M Yatsyk
O B Korsh
Author Affiliation
Department of General Surgery, Ukrainian State Medical University, Kiev, Ukraine.
Source
Drugs Exp Clin Res. 1996;22(3-5):115-22
Date
1996
Language
English
Publication Type
Article
Keywords
Alkaloids - therapeutic use
Antimetabolites, Antineoplastic - therapeutic use
Antineoplastic Agents - therapeutic use
Biopsy
Colorectal Neoplasms - drug therapy - pathology - radiotherapy
Combined Modality Therapy
Comparative Study
Female
Fluorouracil - therapeutic use
Humans
Male
Middle Aged
X-Ray Therapy
Abstract
Ninety six colorectal carcinoma patients were included in a randomised study, 48 were treated with Ukrain monotherapy (15 with metastatic and 33 with nonmetastatic colorectal carcinoma) and 48 with 5-fluorouracil (5-FU) and X-ray therapy (the same randomised groups). The results of therapy including clinical, haematological, immunological and biochemical parameters show that Ukrain has favourable properties in the treatment of colon and rectal cancer as a monotherapy because of its malignotoxic and immunomodulating action. Objective response rate in the group of metastatic colorectal cancer treated by Ukrain was 40%. There was no registered tumour regression in the group treated by 5-FU. Operability is strongly facilitated by pretreatment with Ukrain. The survival rate (up to 21 months) in the Ukrain-treated patients with nonmetastatic colorectal cancer was 78.6% and 33.3% in a corresponding control group. Ukrain is a new effective drug in the therapy of colorectal cancer. It can be useful both for the therapy of metastatic colorectal cancer and for neoadjuvant therapy of nonmetastatic colorectal cancer.
PubMed ID
8899313 View in PubMed
Less detail

Cysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice.

https://arctichealth.org/en/permalink/ahliterature19808
Source
Drugs Exp Clin Res. 2000;26(5-6):301-6
Publication Type
Article
Date
2000
Author
O N Poteryaeva
O V Falameyeva
T A Korolenko
V I Kaledin
S J Djanayeva
J W Nowicky
J. Sandula
Author Affiliation
Russian Academy of Medical Sciences, Institute of Physiology, Novosibirsk, Russia.
Source
Drugs Exp Clin Res. 2000;26(5-6):301-6
Date
2000
Language
English
Publication Type
Article
Keywords
Alkaloids - therapeutic use
Animals
Antineoplastic Agents, Phytogenic - therapeutic use
Cystatins - metabolism
Cysteine Proteinase Inhibitors - metabolism
Liver Neoplasms, Experimental - drug therapy - metabolism
Lung Neoplasms - drug therapy - metabolism
Lymphoma, Diffuse - drug therapy - metabolism
Mice
Neoplasms, Experimental - drug therapy - metabolism
Tissue Distribution
Tumor Markers, Biological
Abstract
Cystatin C is the best known extracellular endogenous cysteine proteinase inhibitor and has been studied as a possible index of tumor growth and as a marker of the effectiveness of antitumor therapy. The aim of this study was to evaluate cystatin C concentrations in murine tumor tissues (compared with other organs not directly involved with tumor development, such as the liver and spleen) during treatment with several antitumor drugs (Ukrain and/or cyclophosphane). Cystatin C concentrations in murine tissues and biological fluids was determined by enzyme-linked immunosorbent (ELISA) assay. The cystatin C ELISA test is a sandwich immunoassay, which uses immobilized rabbit antihuman cystatin C Pab and mouse antihuman cystatin C Mab-HRP (monoclonal antibodies, conjugated with horseradish peroxidase). We observed decreased serum cystatin C concentrations compared with controls in all nontreated tumor models: HA-1 hepatoma (solid and ascitic forms), lung adenocarcinoma (solid and ascitic forms) and LS lymphosarcoma. In the ascitic fluid of mice with HA-1 hepatoma the cystatin C concentration was much lower than in the serum of the same mice (about 20-fold lower). In the HA-1 model of hepatoma cells cystatin C concentration decreased about 2-3-fold compared with the control (intact liver) and Ukrain significantly increased the cystatin C concentration. Cyclophosphane treatment of LS lymphosarcoma significantly increased the cystatin C concentration in serum. Cyclophosphane treatment (50 mg/kg, single injection) increased cystatin C by up to 8-fold more in tumor issue. Ukrain treatment of LS lymphosarcoma was also followed by increased levels of cystatin C in tumor tissue (4-fold); cyclophosphane plus Ukrain had a similar positive effect. In the group with LS lymphosarcoma Ukrain or cyclophosphane plus Ukrain treatment induced a significant increase in cystatin C concentration in liver. Liver cystatin C concentration decreased in the HA-1 hepatoma group and treatment with Ukrain or carboxymethylated beta-1, 3-glucan (CMG) increased this index in both groups. Spleen cystatin C concentrations decreased about 5-fold in LS lymphosarcoma compared with controls and combined treatment with cyclophosphane plus Ukrain restored the index to the normal value. We can conclude that both murine tumors studied were characterized by low cystatin C concentrations in tumor tissues and decreased cystatin C concentrations (to a lesser degree) were also observed in liver and spleen as a result of the "toxic" effect of tumor bearing. Effective treatment in all cases (especially with Ukrain or a combination of cyclophosphane plus Ukrain) induced a significant increase in cystatin C. Obviously, the decrease in cystatin C concentration predominantly in tumor tissue was connected with tumor development and restoration of cystatin C level may be used as a marker of efficacy of antitumor therapy.
PubMed ID
11345042 View in PubMed
Less detail

[Cysteine proteinases and their inhibitors in the development of mouse HA-1 hepatoma and antineoplastic therapy]

https://arctichealth.org/en/permalink/ahliterature17669
Source
Biomed Khim. 2004 Mar-Apr;50(2):172-9
Publication Type
Article
Author
O N Poteriaeva
T A Korolenko
I G Svechnikova
S Ia Zhanaeva
O V Falameeva
V I Kaledin
J W Nowicky
Author Affiliation
Institute of Physiology RAMS, Institute of Biochemistry RAMS, Novosibirsk.
Source
Biomed Khim. 2004 Mar-Apr;50(2):172-9
Language
Russian
Publication Type
Article
Keywords
Alkaloids - therapeutic use
Animals
Antineoplastic Agents - therapeutic use
Ascites - enzymology - metabolism - pathology
Cathepsin B - metabolism
Cathepsin D - metabolism
Cathepsins - metabolism
Cystatins - metabolism
Cysteine Endopeptidases - metabolism
Cysteine Proteinase Inhibitors - metabolism
English Abstract
Liver Neoplasms, Experimental - drug therapy - enzymology - metabolism
Male
Mice
Neoplasm Transplantation
Abstract
Development of murine HA-1 hepatoma was accompanied by increased activity of cathepsin B (in ascitic cells), cathepsin D (in ascitic fluid) and increased activity of procathepsin B. There were some changes of cysteine proteinases in liver and spleen, not involved directly into tumor growth. The most prominent changes included the decreased level of cysteine proteinase inhibitors cystatin C and stefin A in ascitic cells (and to a lesser degree in liver tissue). During tumor development serum cystatin C concentration decreased by 3-times compared to intact mice. Treatment by antitumor drug Ukraine increased life span of mice with HA-1 hepatoma (transplanted intravenously), decreased the increment of tumor weight. In ascite such treatment caused a decrease of number of tumor cells and an increase of number of macrophages. Ukraie (administered once or 5-times in a dose of 0.5 mg per mice) increased cystatin C level, revealing protective mechanism of action.
PubMed ID
15179824 View in PubMed
Less detail

Does the Ukrain preparation protect mice against lethal doses of bacteria?

https://arctichealth.org/en/permalink/ahliterature22888
Source
Drugs Exp Clin Res. 1996;22(3-5):207-11
Publication Type
Article
Date
1996
Author
I. Ciebiada
E. Korczak
J W Nowicky
A. Denys
Author Affiliation
Department of Medical Microbiology, Military Medical Academy, Lódz, Poland.
Source
Drugs Exp Clin Res. 1996;22(3-5):207-11
Date
1996
Language
English
Publication Type
Article
Keywords
Alkaloids - therapeutic use
Animals
Anti-Bacterial Agents - therapeutic use
Escherichia coli Infections - prevention & control
Mice
Mice, Inbred BALB C
Staphylococcal Infections - prevention & control
Time Factors
Abstract
Ukrain, a semi-synthetic preparation obtained from Chelidonium majus L, is used in the treatment of cancer diseases. It has been observed to exert a protective influence in mice infected by influenza viruses. Recently, the influence of the preparation on the survival of mice infected by lethal doses of E. coli and S. aureus has been estimated. This preparation was administered to Balb/c mice subcutaneously in doses of 0.04, 0.4 and 4.0 mg/kg of body weight. Ukrain was given every second day during 20 days, or a short-term before-and-after method at 48, 24 and 2 h before the infection and or 2, 24 and 48 h after the infection of mice. The mice were infected intraperitoneally with E. coli or S. aureus in doses equivalent to 2LD50. Increased survival of mice, depending on the dose of the preparation and the kind of infecting bacterium was observed. The highest survival (50%) occurred in mice infected with E. coli and receiving the amount of the preparation corresponding to 0.4 mg/kg. The lowest survival was observed in mice infected by S. aureus and receiving the preparation in the amount of 4.0 mg/kg. Higher protective effectiveness of the Ukrain preparation was observed in mice when the preparation had been administered during 20 days as compared to the short-term before-and-after regime.
PubMed ID
8899333 View in PubMed
Less detail

The effectiveness of Cytisine versus Nicotine Replacement Treatment for smoking cessation in the Russian Federation.

https://arctichealth.org/en/permalink/ahliterature301949
Source
Int J Drug Policy. 2018 08; 58:121-125
Publication Type
Comparative Study
Journal Article
Observational Study
Date
08-2018
Author
João Mauricio Castaldelli-Maia
Silvia S Martins
Natalie Walker
Author Affiliation
ABC Center for Mental Health Studies, Santo André, SP, Brazil; Department of Psychiatry, Medical School, University of São Paulo, São Paulo, SP, Brazil; Department of Neuroscience, Medical School, Fundação do ABC, Santo André, SP, Brazil. Electronic address: jmcmaia2@gmail.com.
Source
Int J Drug Policy. 2018 08; 58:121-125
Date
08-2018
Language
English
Publication Type
Comparative Study
Journal Article
Observational Study
Keywords
Adult
Alkaloids - therapeutic use
Azocines - therapeutic use
Cross-Sectional Studies
Female
Health Surveys
Humans
Male
Nicotinic Agonists - therapeutic use
Quinolizines - therapeutic use
Russia
Self Medication - statistics & numerical data
Self Report
Smoking Cessation - methods
Tobacco Use Cessation Devices - statistics & numerical data
Treatment Outcome
Young Adult
PubMed ID
29929154 View in PubMed
Less detail

42 records – page 1 of 5.